Endocrine therapies such as selective estrogen receptor modulators (SERMs), selective estrogen receptor downregulators (SERDs) or aromatase inhibitors are the standard-of-care treatment for this breast cancer subset, and these therapies have significantly reduced mortality and disease recurrence [2]. This evidence concerns the gene ESR1 and breast carcinoma.